Literature DB >> 14707823

Photodynamic therapy for chronic central serous chorioretinopathy.

Felice Cardillo Piccolino1, Chiara M Eandi, Luca Ventre, Roberta C Rigault de la Longrais, Federico M Grignolo.   

Abstract

PURPOSE: To determine whether photodynamic therapy (PDT) is effective for treatment of chronic central serous chorioretinopathy (CSC).
METHODS: Sixteen eyes with chronic CSC and macular detachment documented by optical coherence tomography (OCT) received PDT guided by indocyanine green (ICG) angiography according to the parameters outlined in the TAP Study. One or more laser spots were applied to the areas of choroidal vascular hyperpermeability that corresponded to retinal pigment epithelium decompensation. Patients were observed for 6 to 12 months. Two PDT sessions 1 month apart were performed on 2 eyes. Examinations included visual acuity measurement, fundus biomicroscopy, fluorescein and ICG angiography, and OCT.
RESULTS: Macular exudation resolved completely in 13 eyes (81%) and partially regressed in 3. Choriocapillaris hypoperfusion was shown by ICG angiography for several months at the site of PDT application. Visual acuity improved 1 to 4 lines in 11 eyes and was unchanged in 5 eyes.
CONCLUSIONS: ICG-guided PDT performed according to the parameters outlined by the TAP Study seems effective for treating chronic CSC. Further studies are needed to verify treatment safety and the time and rate of recurrences.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14707823     DOI: 10.1097/00006982-200312000-00002

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  98 in total

1.  [Experiences with chronic central serous chorioretinopathy treated with half-dose photodynamic therapy and verteporfin].

Authors:  M Töteberg-Harms; M Kurz-Levin; J Fleischhauer; R Windisch
Journal:  Ophthalmologe       Date:  2011-10       Impact factor: 1.059

2.  Effects of photodynamic therapy with verteporfin for the treatment of chronic central serous chorioretinopathy: An uncontrolled, open-label, observational study.

Authors:  Yildirim Bayezit Sakalar; Ugur Keklikci; Kaan Unlu; Mehmet Fuat Alakus; Ismail Hamdi Kara
Journal:  Curr Ther Res Clin Exp       Date:  2010-06

3.  Selective retina therapy in patients with central serous chorioretinopathy.

Authors:  H Elsner; E Pörksen; C Klatt; A Bunse; D Theisen-Kunde; R Brinkmann; R Birngruber; H Laqua; J Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-12       Impact factor: 3.117

4.  Optical coherence tomography characterisation of idiopathic central serous chorioretinopathy.

Authors:  J A Montero; J M Ruiz-Moreno
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

5.  Half dose verteporfin PDT for central serous chorioretinopathy.

Authors:  J M Stewart
Journal:  Br J Ophthalmol       Date:  2006-07       Impact factor: 4.638

6.  A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports).

Authors:  Mitzy E Torres-Soriano; Gerardo García-Aguirre; Verónica Kon-Jara; Orlando Ustariz-Gonzáles; Maura Abraham-Marín; Michael D Ober; Hugo Quiroz-Mercado
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-06-04       Impact factor: 3.117

7.  Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  R Uetani; Y Ito; K Oiwa; K Ishikawa; H Terasaki
Journal:  Eye (Lond)       Date:  2012-05       Impact factor: 3.775

Review 8.  Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review.

Authors:  Y-R Chung; E J Seo; H M Lew; K H Lee
Journal:  Eye (Lond)       Date:  2013-11-08       Impact factor: 3.775

9.  Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Helena Vasconcelos; Inês Marques; A Rita Santos; Pedro Melo; Isabel Pires; João Figueira; José Faria de Abreu; M Luz Cachulo; Rufino Silva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-07       Impact factor: 3.117

10.  One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.

Authors:  Yasuhiro Ohkuma; Takaaki Hayashi; Tsutomu Sakai; Akira Watanabe; Hiroshi Tsuneoka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-02       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.